WO2004043344A3 - Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same - Google Patents

Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same Download PDF

Info

Publication number
WO2004043344A3
WO2004043344A3 PCT/US2003/032737 US0332737W WO2004043344A3 WO 2004043344 A3 WO2004043344 A3 WO 2004043344A3 US 0332737 W US0332737 W US 0332737W WO 2004043344 A3 WO2004043344 A3 WO 2004043344A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
same
treatment
myeloid leukemia
acute myeloid
Prior art date
Application number
PCT/US2003/032737
Other languages
French (fr)
Other versions
WO2004043344A2 (en
Inventor
Mary G Hoffee
Daniel Tavares
Robert J Lutz
Original Assignee
Immunogen Inc
Mary G Hoffee
Daniel Tavares
Robert J Lutz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2004551530A priority Critical patent/JP5354835B2/en
Priority to NZ539395A priority patent/NZ539395A/en
Application filed by Immunogen Inc, Mary G Hoffee, Daniel Tavares, Robert J Lutz filed Critical Immunogen Inc
Priority to MXPA05004712A priority patent/MXPA05004712A/en
Priority to EA200500778A priority patent/EA010570B1/en
Priority to CA2504818A priority patent/CA2504818C/en
Priority to AU2003285878A priority patent/AU2003285878B2/en
Priority to BR0316101-3A priority patent/BR0316101A/en
Priority to DK03779105.0T priority patent/DK1578446T3/en
Priority to SI200332425T priority patent/SI1578446T1/en
Priority to CN200380102406.0A priority patent/CN1795009B/en
Priority to EP03779105.0A priority patent/EP1578446B1/en
Priority to ES03779105.0T priority patent/ES2539627T3/en
Publication of WO2004043344A2 publication Critical patent/WO2004043344A2/en
Publication of WO2004043344A3 publication Critical patent/WO2004043344A3/en
Priority to IL168295A priority patent/IL168295A/en
Priority to NO20052693A priority patent/NO338498B1/en
Priority to HK06111884.0A priority patent/HK1091132A1/en
Priority to IL211385A priority patent/IL211385A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of said antibodies, humanized and resurfaced versions of said antibodies, functional equivalents and improved versions of said antibodies, immunoconjugates and compositions comprising said antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding the antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing the antibodies.
PCT/US2003/032737 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same WO2004043344A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SI200332425T SI1578446T1 (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
DK03779105.0T DK1578446T3 (en) 2002-11-07 2003-11-05 ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
MXPA05004712A MXPA05004712A (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same.
EA200500778A EA010570B1 (en) 2002-11-07 2003-11-05 Anti cd33 antibody and method for using thereof
CA2504818A CA2504818C (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
AU2003285878A AU2003285878B2 (en) 2002-11-07 2003-11-05 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
NZ539395A NZ539395A (en) 2002-11-07 2003-11-05 Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
JP2004551530A JP5354835B2 (en) 2002-11-07 2003-11-05 Anti-CD33 antibody and method for treating acute myeloid leukemia using the same
BR0316101-3A BR0316101A (en) 2002-11-07 2003-11-05 Anticd33 antibodies and process for treating acute meloid leukemia using the same.
EP03779105.0A EP1578446B1 (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
CN200380102406.0A CN1795009B (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
ES03779105.0T ES2539627T3 (en) 2002-11-07 2003-11-05 Anti-CD33 antibodies and method for the treatment of acute myeloid leukemia using them
IL168295A IL168295A (en) 2002-11-07 2005-04-14 Anti-cd33 antibodies or epitope-binding fragments thereof and pharmaceutical compositions containing the same
NO20052693A NO338498B1 (en) 2002-11-07 2005-06-06 Anti-CD33 antibodies and methods for the treatment of acute myeloid leukemia using them.
HK06111884.0A HK1091132A1 (en) 2002-11-07 2006-10-27 Anti-cd33 antibodies and the use thereof -cd33
IL211385A IL211385A0 (en) 2002-11-07 2011-02-23 Anti-cd33 antibodies or epitope-binding fragments thereof and pharmaceutical compositions containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42433202P 2002-11-07 2002-11-07
US60/424,332 2002-11-07

Publications (2)

Publication Number Publication Date
WO2004043344A2 WO2004043344A2 (en) 2004-05-27
WO2004043344A3 true WO2004043344A3 (en) 2004-12-09

Family

ID=32312793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032737 WO2004043344A2 (en) 2002-11-07 2003-11-05 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same

Country Status (25)

Country Link
US (10) US7557189B2 (en)
EP (1) EP1578446B1 (en)
JP (1) JP5354835B2 (en)
KR (1) KR20050059332A (en)
CN (2) CN1795009B (en)
AU (1) AU2003285878B2 (en)
BR (1) BR0316101A (en)
CA (1) CA2504818C (en)
CO (1) CO5580797A2 (en)
CR (1) CR7853A (en)
CY (1) CY1116406T1 (en)
DK (1) DK1578446T3 (en)
EA (1) EA010570B1 (en)
EC (1) ECSP055831A (en)
ES (1) ES2539627T3 (en)
HK (1) HK1091132A1 (en)
HU (1) HUE026914T2 (en)
IL (2) IL168295A (en)
MX (1) MXPA05004712A (en)
NO (1) NO338498B1 (en)
NZ (1) NZ539395A (en)
PT (1) PT1578446E (en)
SI (1) SI1578446T1 (en)
WO (1) WO2004043344A2 (en)
ZA (1) ZA200503075B (en)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795009B (en) * 2002-11-07 2014-07-09 伊谬诺金公司 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
JP4852046B2 (en) 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー Binding molecules for the treatment and detection of cancer
EP1853322B1 (en) * 2005-02-11 2014-06-25 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
ES2673822T3 (en) 2006-07-18 2018-06-25 Sanofi Antagonist antibody against EphA2 for cancer treatment
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2084527A4 (en) * 2006-11-02 2011-07-27 Seattle Genetics Inc Methods of treating neoplastic, autoimmune and inflammatory diseases
LT2644205T (en) 2007-04-12 2018-12-10 The Brigham And Women`S Hospital, Inc. Targeting ABCB5 for cancer therapy
ES2435779T3 (en) 2007-07-19 2013-12-23 Sanofi Cytotoxic agents comprising new tomaimycin derivatives and their therapeutic use
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
KR20220035504A (en) 2008-04-30 2022-03-22 이뮤노젠 아이엔씨 Cross-linkers and their uses
CN106188295A (en) 2009-04-20 2016-12-07 牛津生物疗法有限公司 It is specific to the antibody of cadherins 17
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
FR2947269B1 (en) 2009-06-29 2013-01-18 Sanofi Aventis NEW ANTICANCER COMPOUNDS
FR2949469A1 (en) 2009-08-25 2011-03-04 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011028683A1 (en) 2009-09-03 2011-03-10 Schering Corporation Anti-gitr antibodies
DE102009045006A1 (en) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 antibodies and their use for immuno-targeting in the treatment of CD33-associated diseases
AR078471A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis MAITANSINOID COMPOUNDS AND THE USE OF THESE TO PREPARE CONJUGATES WITH AN ANTIBODY WHICH ARE USED AS ANTI-BANKING AGENTS AND THE PREPARATION PROCEDURE OF THESE CONJUGATES
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
US8524240B2 (en) 2009-10-26 2013-09-03 Djordje Atanackovic Diagnosis and therapy of hematological malignancies
WO2011053783A2 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
CN103037900B (en) 2010-02-24 2016-04-06 伊缪诺金公司 Folacin receptor 1 antibody and immunoconjugates with and uses thereof
JP2013520999A (en) 2010-03-04 2013-06-10 ベット・セラピューティクス・インコーポレイテッド Monoclonal antibody against CD52
AU2011221553B2 (en) * 2010-03-04 2016-05-26 Vet Therapeutics Inc. Monoclonal antibodies directed to CD20
US9616120B2 (en) * 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
FR2963007B1 (en) 2010-07-26 2013-04-05 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
WO2012054084A2 (en) * 2010-10-20 2012-04-26 Oxford Biotherapeutics Ltd. Antibodies
WO2012074097A1 (en) * 2010-12-03 2012-06-07 協和発酵キリン株式会社 Anti-cd33 antibody
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
US9534000B2 (en) 2011-02-15 2017-01-03 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
SI2691155T1 (en) 2011-03-29 2019-03-29 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SG193997A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Process for manufacturing conjugates of improved homogeneity
CN103842383B (en) 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 Polyspecific FAB fusion proteins and its application method
CA2836927A1 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
KR102096224B1 (en) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Polypeptide constructs and uses thereof
BR112014012539B1 (en) 2011-11-23 2022-12-20 Medimmune, Llc ANTIBODY SPECIFICALLY BINDING HER3, COMPOSITION COMPRISING THE SAME, AND USES OF THE ANTIBODY
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
CN102768283B (en) * 2012-07-23 2015-03-04 北京大学人民医院 Kit for detecting or supplementarily detecting medullary leukemia cell differentiation stages
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
RU2668824C2 (en) 2012-08-31 2018-10-02 Иммьюноджен Инк. Diagnostic assays and kits for detection of folate receptor 1
SG10201702737TA (en) 2012-10-04 2017-05-30 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
PL2766048T3 (en) 2012-10-12 2015-05-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN105142674B (en) 2013-03-13 2018-11-13 麦迪穆有限责任公司 Pyrrolobenzodiazepines Zhuo and its conjugate
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
PT3016512T (en) 2013-07-05 2020-02-24 H Lee Moffitt Cancer Ct & Res Soluble cd33 for treating myelodysplastic syndromes (mds)
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EA201691214A1 (en) * 2013-12-13 2016-12-30 Дженентек, Инк. ANTIBODIES TO CD33 AND IMMUNOCONJUGATES
CN105873614B (en) * 2013-12-16 2020-10-30 基因泰克公司 Peptidomimetic compounds and antibody-drug conjugates thereof
KR102170533B1 (en) 2014-04-03 2020-10-27 셀렉티스 Cd33 specific chimeric antigen receptors for cancer immunotherapy
CA2948275C (en) 2014-04-08 2023-10-17 Boston Pharmaceuticals Inc. Binding molecules specific for il-21 and uses thereof
JP2017512765A (en) 2014-04-11 2017-05-25 メディミューン，エルエルシー Bispecific HER2 antibody
WO2015179400A2 (en) * 2014-05-20 2015-11-26 Immunogen,Inc. Methods for characterizing and treating acute myeloid leukemia
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
MA42561A (en) 2014-09-02 2018-04-25 Immunogen Inc METHODS FOR FORMULATING ANTIBODY-DRUG CONJUGATE COMPOSITIONS
PL3189056T3 (en) 2014-09-03 2020-11-02 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
JP2017527562A (en) 2014-09-03 2017-09-21 イミュノジェン・インコーポレーテッド Cytotoxic benzodiazepine derivatives
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9867831B2 (en) * 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CA2962275C (en) * 2014-10-23 2019-11-05 Singh Biotechnology, Llc Single domain antibodies directed against intracellular antigens
JP6755866B2 (en) 2014-11-10 2020-09-16 メディミューン リミテッド CD73-specific binding molecule and its use
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
US10413615B2 (en) 2014-11-19 2019-09-17 Immunogen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
IL307913A (en) * 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of acute myeloid leukemiaanti-cd38 antibodies for treatment of ac
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
US11014989B2 (en) 2015-01-26 2021-05-25 Cellectis Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
AU2016271113B2 (en) 2015-05-29 2022-09-08 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
JP7497953B2 (en) 2015-06-12 2024-06-11 アレクトル エルエルシー Anti-CD33 antibodies and methods of use thereof
EP3307771A2 (en) * 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
SI3313845T1 (en) 2015-06-29 2021-01-29 Immunogen, Inc. Conjugates of cysteine engineered antibodies
SI3313884T1 (en) 2015-06-29 2021-04-30 Immunogen, Inc. Anti-cd123 antibodies and conjugates and derivatives thereof
SI3374398T1 (en) 2015-11-10 2020-07-31 Medimmune, Llc Binding molecules specific for asct2 and uses thereof
ES2873846T3 (en) 2015-11-19 2021-11-04 Revitope Ltd Functional Antibody Fragment Complementation for a Two-Component System for Targeted Elimination of Unwanted Cells
JP2019501139A (en) 2015-11-25 2019-01-17 イミュノジェン・インコーポレーテッド Pharmaceutical formulations and uses thereof
EP3411077A1 (en) 2016-02-05 2018-12-12 ImmunoGen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
EP3426680A4 (en) 2016-03-10 2020-03-11 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
WO2017157305A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR20220119529A (en) 2016-06-02 2022-08-29 애브비 인코포레이티드 Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017210621A1 (en) 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
US11191771B2 (en) 2016-06-09 2021-12-07 Seagen Inc. Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors
EP3515947B1 (en) * 2016-09-20 2024-05-29 Aronora, Inc. Novel antibodies against factor xi and uses thereof
CN109862919A (en) 2016-10-11 2019-06-07 免疫医疗有限公司 The therapeutic agent that antibody-drug conjugates combined immunization mediates
RU2019114863A (en) * 2016-11-02 2020-12-03 Иммуноджен, Инк. COMBINED TREATMENT WITH ANTIBODY-DRUG CONJUGATES AND PARP INHIBITORS
CR20190297A (en) 2016-11-23 2019-11-01 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
US10287256B2 (en) 2016-11-23 2019-05-14 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibodies and immunoconjugates and uses thereof
CN110366431B (en) 2017-02-28 2023-07-18 伊缪诺金公司 Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof
TW201839001A (en) 2017-04-20 2018-11-01 美商伊繆諾金公司 Cytotoxic benzodiazepine derivatives and conjugates thereof
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
BR112019023855B1 (en) 2017-05-12 2021-11-30 Harpoon Therapeutics, Inc MESOTHELIN BINDING PROTEINS
MA49152A (en) * 2017-05-17 2020-03-25 Immunogen Inc ANTI-CD33 IMMUNOCONJUGATE DOSAGE SCHEDULES
JP7299160B2 (en) * 2017-08-03 2023-06-27 アレクトル エルエルシー ANTI-CD33 ANTIBODY AND METHOD OF USE THEREOF
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
WO2019060707A1 (en) 2017-09-22 2019-03-28 Immunogen, Inc. Methods of preventing methionine oxidation in immunoconjugates
AU2018346955A1 (en) 2017-10-13 2020-04-30 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US20190160089A1 (en) 2017-10-31 2019-05-30 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
TWI827575B (en) 2017-12-28 2024-01-01 美商伊繆諾金公司 Benzodiazepine derivatives
CN111989117A (en) 2018-02-14 2020-11-24 维埃拉生物股份有限公司 Antibodies to the ligand of the mcdonald cat sarcoma (FMS) -like tyrosine kinase 3 receptor (FLT3L) and their use for the treatment of autoimmune and inflammatory diseases
JP7398380B2 (en) * 2018-03-08 2023-12-14 フェインズ セラピューティクス，インコーポレーテッド Anti-claudin 18.2 antibody and its use
JP7386800B2 (en) * 2018-03-14 2023-11-27 メモリアル スローン－ケタリング キャンサー センター Anti-polysialic acid antibody and its use
TW202003048A (en) 2018-05-15 2020-01-16 美商伊繆諾金公司 Combination treatment with antibody-drug conjugates and FLT3 inhibitors
CN113286616A (en) 2018-05-23 2021-08-20 Adc治疗有限公司 Molecular adjuvant
JP2021525068A (en) * 2018-05-23 2021-09-24 ナショナル ユニバーシティ オブ シンガポール Blocking CD2 surface expression and expressing chimeric antigen receptor for immunotherapy of T cell malignancies
JOP20190116A1 (en) 2018-05-24 2019-11-24 Janssen Biotech Inc Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
SG11202101875VA (en) * 2018-08-28 2021-03-30 Ambrx Inc Anti-cd3 antibody folate bioconjugates and their uses
SG11202101552SA (en) 2018-08-31 2021-03-30 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3849565A4 (en) * 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2020068058A1 (en) * 2018-09-25 2020-04-02 Academia Sinica Anti-siglec antibody, pharmaceutical composition comprising the same, and uses thereof
WO2020077258A1 (en) * 2018-10-12 2020-04-16 Jeanmarie Guenot Cd33×cd3 binding proteins for treating inflammatory conditions and diseases
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
JP7463366B2 (en) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド Novel anti-Zika virus antibodies and uses thereof
KR20220022112A (en) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 Methods of Preparing Cell-Binding Agent-Drug Conjugates
JP2022529583A (en) 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド Its complex with cytotoxic bis-benzodiazepine derivatives and cell binding agents for inhibiting aberrant cell proliferation or treating proliferative disorders
WO2020219287A1 (en) 2019-04-26 2020-10-29 Immunogen, Inc. Camptothecin derivatives
CN114007642A (en) 2019-04-30 2022-02-01 森迪生物科学公司 Chimeric receptors and methods of use thereof
US20230081720A1 (en) 2019-05-20 2023-03-16 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
JP2022538117A (en) * 2019-06-26 2022-08-31 メモリアル スローン ケタリング キャンサー センター Anti-CD33 antibodies for treating cancer
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN116670268A (en) 2019-11-22 2023-08-29 免疫医疗有限公司 Fusion proteins comprising E2 ubiquitin or ubiquitin-like conjugation domains and targeting domains for specific protein degradation
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CN116234568A (en) 2020-07-07 2023-06-06 生物技术公司 Therapeutic RNAs for HPV-positive cancers
US11795225B2 (en) 2020-09-11 2023-10-24 Medimmune Limited Therapeutic binding molecules
WO2022053685A2 (en) 2020-09-12 2022-03-17 Medimmune Limited A scoring method for an anti-b7h4 antibody-drug conjugate therapy
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN116761635A (en) 2020-11-24 2023-09-15 诺华股份有限公司 BCL-XL inhibitor antibody drug conjugates and methods of use thereof
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022236492A1 (en) 2021-03-18 2023-10-26 Medimmune Limited Therapeutic binding molecule that binds to ccr9
WO2022241057A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
IL309831A (en) 2021-07-13 2024-02-01 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
TW202348252A (en) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 Combination therapies for treatment of cancer with therapeutic binding molecules
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
GB202219154D0 (en) 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010332A1 (en) * 1992-11-04 1994-05-11 Medarex, Inc. HUMANIZED ANTIBODIES TO Fc RECEPTORS FOR IMMUNOGLOBULIN G ON HUMAN MONONUCLEAR PHAGOCYTES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE69033631T2 (en) 1989-12-14 2001-05-17 Sloan Kettering Inst Cancer THERAPEUTIC USE OF THE HYPERVARIABLE REGION OF THE MONOCLONAL ANTIBODY M195 AND CONSTRUCTS THEREOF
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US6417337B1 (en) 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
ATE444309T1 (en) * 2000-08-08 2009-10-15 Immunomedics Inc IMMUNOTHERAPY FOR CRONIC MYELOCYTIC LEUKEMIA WITH NAKED ANTI-NCA-90 ANTIBODIES
CA2434762A1 (en) * 2001-01-26 2002-09-19 Joseph M. Patti Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
CN1795009B (en) * 2002-11-07 2014-07-09 伊谬诺金公司 Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
JP2008538365A (en) * 2005-04-15 2008-10-23 イミュノジェン・インコーポレーテッド Methods for eliminating heterogeneous or mixed cell populations within a tumor
US8563700B2 (en) * 2008-06-16 2013-10-22 Immunogen, Inc. Synergistic effects
WO2015179400A2 (en) * 2014-05-20 2015-11-26 Immunogen,Inc. Methods for characterizing and treating acute myeloid leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010332A1 (en) * 1992-11-04 1994-05-11 Medarex, Inc. HUMANIZED ANTIBODIES TO Fc RECEPTORS FOR IMMUNOGLOBULIN G ON HUMAN MONONUCLEAR PHAGOCYTES

Also Published As

Publication number Publication date
DK1578446T3 (en) 2015-06-29
HUE026914T2 (en) 2016-08-29
EP1578446B1 (en) 2015-04-08
JP5354835B2 (en) 2013-11-27
KR20050059332A (en) 2005-06-17
ES2539627T3 (en) 2015-07-02
IL168295A (en) 2011-02-28
US20140248267A1 (en) 2014-09-04
US7342110B2 (en) 2008-03-11
AU2003285878B2 (en) 2011-04-28
CA2504818C (en) 2013-04-23
CY1116406T1 (en) 2017-02-08
CO5580797A2 (en) 2005-11-30
MXPA05004712A (en) 2005-11-23
EA010570B1 (en) 2008-10-30
ZA200503075B (en) 2006-09-27
CN102875680A (en) 2013-01-16
US8119787B2 (en) 2012-02-21
US20050118183A1 (en) 2005-06-02
US8747851B2 (en) 2014-06-10
AU2003285878A1 (en) 2004-06-03
US8337855B2 (en) 2012-12-25
US20160362490A1 (en) 2016-12-15
HK1091132A1 (en) 2007-01-12
JP2006505277A (en) 2006-02-16
EP1578446A4 (en) 2008-07-30
CN1795009B (en) 2014-07-09
NZ539395A (en) 2009-01-31
CN102875680B (en) 2015-04-22
US20110008840A1 (en) 2011-01-13
IL211385A0 (en) 2011-04-28
EP1578446A2 (en) 2005-09-28
BR0316101A (en) 2005-09-27
US9359442B2 (en) 2016-06-07
PT1578446E (en) 2015-07-22
ECSP055831A (en) 2005-08-11
US20110206700A1 (en) 2011-08-25
WO2004043344A2 (en) 2004-05-27
NO338498B1 (en) 2016-08-22
CN1795009A (en) 2006-06-28
US20180362646A1 (en) 2018-12-20
SI1578446T1 (en) 2015-07-31
US10000566B2 (en) 2018-06-19
US20090291090A1 (en) 2009-11-26
US7557189B2 (en) 2009-07-07
CR7853A (en) 2005-12-16
NO20052693L (en) 2005-06-06
US20060177455A1 (en) 2006-08-10
EA200500778A1 (en) 2006-02-24
CA2504818A1 (en) 2004-05-27
NO20052693D0 (en) 2005-06-06
US20080167458A1 (en) 2008-07-10
US20130078241A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
WO2004043344A3 (en) Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
WO2007126876A3 (en) Anti-igf-ir antibodies and uses thereof
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
AU2003271174A1 (en) Double specific antibodies substituting for functional protein
WO2009094148A3 (en) Ron antibodies and uses thereof
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2003059951A3 (en) Novel anti-igf-ir antibodies and uses thereof
BE2016C008I2 (en)
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
EA200800094A1 (en) ANTIBODIES CD19 AND THEIR USE
WO2006082515A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2001000245A3 (en) HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2004080418A3 (en) Nucleic acid compounds for inhibiting angiogenesis and tumor growth
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2005016241A3 (en) Synthetic chemokine receptor ligands and methods of use thereof
WO2004048521A3 (en) Composition and method for treating lupus nephritis
WO2004058158A3 (en) Treatment of metastatic cancer with the b-subunit of shiga toxin
WO2001049729A3 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
EP1434799A4 (en) Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans
WO2005049651A3 (en) Cancer diagnosis and therapy
WO2006021210A3 (en) Binding member towards pneumolysin
WO2006091326A8 (en) Anti-prl-3 antibodies and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 539395

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 168295

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/03075

Country of ref document: ZA

Ref document number: 200503075

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003285878

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1565/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004712

Country of ref document: MX

Ref document number: 20038A24060

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2504818

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020057008083

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004551530

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003779105

Country of ref document: EP

Ref document number: 05048853

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: CR2005-007853

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200500778

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020057008083

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0316101

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 2003779105

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 211385

Country of ref document: IL